SEARCH

SEARCH BY CITATION

References

  • Alexanian, R., Haut, A., Khan, A.U., Lane, M., McKelvey, E.M., Migliore, P.J., Stuckey, Jr, W.J. & Wilson, H.E. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 208, 16801685.
  • Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B, Bataille, R. & InterGroupe Francophone du Myelome (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 24952502.
  • Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I.Y., Bourhis, J.H., Garderet, L., Sotto, J.J., Michallet, M., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Dumonté, C., Caillot, D., Mathiot, C. & Avet-Loiseau, H. (2005) Maintenance treatment with thalidomide after autologous transplantation for myeloma: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome. Blood, 106, 1148 (abstr).
  • Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.J., Harousseau, J.L., Minvielle, S., Bataille, R.& Intergroupe Francophone du Myelome (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 21852191.
  • Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 13531356.
  • Barlogie, B., Hall, R., Zander, A., Dicke, K. & Alexanian, R. (1986) High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood, 67, 12981301.
  • Barlogie, B., Alexanian, R., Dicke, K.A., Zagars, G., Jagannath, S. & Horwitz, L. (1987) High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood, 70, 869872.
  • Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. & Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789793.
  • Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., Van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 10211030.
  • Bergsagel, D.E., Sprague, C.C., Austin, C. & Griffith, K.M. (1962) Evaluation of new chemotherapeutic agents in the treatment of myeloma IV: phenylalanine mustard. Cancer Chemotherapy Reports, 2, 8799.
  • Cox, D.R. (1972) Regression tables and life tables. Journal of the Royal Statistical Society: Series B, 34, 187202.
  • Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 40084010.
  • Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M, Renaud, M., Harousseau, J.L., Pegourie, B., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, J., Troncy, J., Dorvaus, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Kolb, B. & Bauters, F. (2005) Major superiority of melphalan–prednisone (MP) +  thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood, 106, 780 (abstr).
  • Fermand, J.P., Chevret, S., Ravaud, P., Divine, M., Leblond, V., Dreyfus, F., Mariette, X. & Brouet, J.C. (1993) High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood, 82, 20052009.
  • Gianni, A.M., Siena, S., Bregni, M., Tarella, C., Stern, A.C., Pileri, A. & Bonadonna, G. (1989) Granulocyte–macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet, 2, 580585.
  • Gregory, W.M., Richards, M.A. & Malpas, J.S. (1992) Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334342.
  • Harousseau, J.L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H., Cailoot, D., Boasson, M. & Abgrall, J.F. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood, 85, 30773085.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163170.
  • Mateos, M.V., Hernandez, M., Mediavilla, J.D., Palomera, L., Moro, M.J., Hernández, J., Lahuerta, J.J., De la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Arriba, F., Alegre, A., Rivas, P., García-Laraña, J., Ribera, J.M., Carrera, D., Bladé, J., Prósper, F., Esseltine, D.L., Van De Velde, H., Schenkein, D. & San Miguel, J.F. (2005) A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma (MM) patients. Blood, 106, 786 (abstr).
  • McElwain, T.J. & Powles, R.L. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, 2, 822824.
  • Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P., Boccadoro, M. & Italian Multiple Myeloma Network (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet, 367, 825831.
  • Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R., Greipp, P.R. & Eastern Cooperative Oncology Group (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431436.
  • Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 30633067.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 26092617.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 34, 15651571.
  • Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. & Sawyer, J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 42504256.
  • Zhan, F., Hardin, A., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., Van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, Jr, J. (2002) Global gene expression profiling of multiple myeloma monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood, 99, 17451757.